This announcement has been amended to add the COVID-19 vaccine mandate to the conditions of employment.
This position is subject to the COVID-19 vaccine mandate as a condition of employment.
The National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH) is seeking exceptional candidates for the position of Director, Division of Therapeutics and Medical Consequences (DTMC). NIDA’s mission is to advance science on the causes and consequences of drug use and addiction and to apply that knowledge to improve individual and public health.
DTMC focuses on the development of new therapies for the treatment of substance use disorders (SUDs) and related medical and psychiatric conditions. To accomplish this mission, the division a) plans and directs studies to identify, evaluate and develop new medications and devices for Food and Drug Administration (FDA) review and approval; b) develops and administers a national program of basic and clinical research to develop innovative immunological, pharmacological, and behavioral treatment approaches; c) supports training in the pre-clinical and clinical sciences; d) collaborates with the pharmaceutical industry and other federal entities to facilitate medications development for substance use disorders; e) and works closely with the FDA to assure that the research designed to demonstrate safety and efficacy is evaluated and leads to approval in the most expeditious manner.
Additionally, DTMC conducts research on the medical consequences of substance use disorders. To accomplish this mission, the division administers a national and international program on the medical consequences of licit and illicit drug use and co-occurring viral, bacterial, and fungal infections. The program has concentrated on HIV, Hepatitis C, and tuberculosis infections, with a special emphasis on co-infection of HIV and Hepatitis C infection. Other areas of programmatic emphasis are drug-drug interactions between treatment medications for substance use disorders and medications for treatment of infectious diseases in populations experiencing drug usage.
The DTMC Director directs an extramural scientific program of national and international scope within NIDA. This position reports to the NIDA Director and is a "top 5" position. The primary goal of the division is to improve the treatment of substance use disorders through the development of new medications, devices, and behavioral therapies. Improving treatment of infectious diseases in substance use disorder populations is another priority goal of the division. To implement these goals, the Director reviews current programs and develops and implements new initiatives, with a staff of 27 extramural scientists and 3 administrative staff, through a process of meetings with outside advisors, requests for applications and program announcements, contract solicitations and allocation of contract resources for specific projects, collaborations with the pharmaceutical industry, scientific presentations, and publications in the peer-reviewed literature. DTMC has an operating budget of $6M per year and manages a grants and R&D contract portfolio of over $200M, including one of the NIH Helping to End Addiction Long-term (HEAL) Initiative’s largest programs.
NIDA is a component of the NIH, headquartered in Bethesda, Maryland. Appointment to this position may have a Bethesda, MD, duty location, or may be authorized for a remote duty location elsewhere in the United States.
The successful candidate will possess an M.D., and/or Ph.D. degree, and will have expert-level knowledge of neuropsychopharmacology and advanced experience in medication and device development, including the design and execution of multisite clinical trials. Leadership experience in medication and device development within the biotechnology or pharmaceutical sectors is highly desirable. The individual must also have demonstrated ability to manage personnel, budgets, and timelines across multiple fiscal years. A track-record of industry/academic excellence and outstanding scientific contributions to the treatment of substance use disorders is expected. The successful candidate will demonstrate a commitment to diversity, equity, and inclusion.
In accordance with Executive Order 14043, Federal employees are required to be fully vaccinated against COVID-19 regardless of the employee’s duty location or work arrangement (e.g., telework, remote work, etc.), subject to exceptions that may be required by law. If selected, you will be required to submit proof of vaccination by November 22, 2021 or before your entrance on duty if you are selected after the compliance date. Your HR Consultant will provide a list of documents acceptable as proof of vaccination and instructions for how to submit a request for a legally required exception, if needed, to comply with vaccination requirement.
The successful candidate for this position will be appointed at a salary commensurate with their qualifications. A recruitment or relocation bonus may be available, and relocation expenses may be paid. Full Federal benefits, including leave, health and life insurance, long term care insurance, retirement, and savings plan (401K equivalent) will be provided. The successful candidate is subject to a background investigation and public financial disclosure report prior to the effective date of the appointment.
Expanded/Maximum Telework Posture
Due to COVID-19, the agency is currently in a maximum telework posture. If selected, you may be expected to telework upon your appointment. As employees are permitted to return to the office, you may be required to report to the duty station listed on this announcement within 30 calendar days of receiving notice to do so, even if your home/temporary telework site is located outside the local commuting area. Your position may be eligible for workplace flexibilities which may include remote work or telework options, and/or flexible work scheduling. These flexibilities may be requested in accordance with the HHS Workplace Flexibilities policy.
Equal Employment Opportunity
Selection for this position will be based solely on merit, with no discrimination for non-merit reasons such as race, color, religion, gender, sexual orientation, national origin, political affiliation, marital status, disability, age, or membership or non-membership in an employee organization. The NIH encourages the application and nomination of qualified women, minorities, and individuals with disabilities.
Standards of Conduct/Financial Disclosure
The NIH inspires public confidence in our science by maintaining high ethical principles. NIH employees are subject to federal government-wide regulations and statutes as well as agency-specific regulations described at the NIH Ethics Website. We encourage you to review this information. The position is subject to a background investigation and requires the incumbent to complete a public financial disclosure report prior to the effective date of the appointment and be approved by the NIH Ethics Office.
Applicants who have completed part or all of their education outside of the U.S. must have their foreign education evaluated by an accredited organization to ensure that the foreign education is equivalent to education received in accredited educational institutions in the U.S. We will only accept the completed foreign education evaluation. For more information on Foreign Education verification, visit the National Association of Credential Evaluation Services (NACES) website. Verification must be received prior to the effective date of the appointment.
NIH provides reasonable accommodations to applicants with disabilities. If you require reasonable accommodation during any part of the application and hiring process, please notify us at NIDA_DTMC_Director_Search@nih.gov. The decision on granting reasonable accommodation will be made on a case-by-case basis.